LeMaitre Vascular, Inc. LMAT
78.29 USD +0.64 (+0.82%)
Regular-session close
78.29 0.00 0.00%
After hours · Nov 13, 4:02 PM ET
77.91 Day range 80.21
77.65 52-week range 117.39
- YTD
- -3.46%
- 1 year
- -12.66%
News
seekingalpha.com LeMaitre Vascular, Inc. (LMAT) Q3 2026 Earnings Call Transcript LeMaitre Vascular, Inc. ( LMAT ) Q3 2026 Earnings Call November 4, 2026 5:00 PM EST Company Participants Dorian LeBlanc - Chief Financial Officer George LeMaitre - Chairman & CEO Conference Call…
globenewswire.com LeMaitre to Participate in Upcoming Investor Conferences BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.
benzinga.com Wells Fargo Maintains Equal-Weight on LeMaitre Vascular, Lowers Price Target to $86 Wells Fargo analyst Nathan Treybeck maintains LeMaitre Vascular (NASDAQ:LMAT) with a Equal-Weight and lowers the price target from $94 to $86.
benzinga.com Citizens Maintains Market Outperform on LeMaitre Vascular, Lowers Price Target to $110 Citizens analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:LMAT) with a Market Outperform and lowers the price target from $127 to $110.
marketbeat.com LeMaitre Vascular Q3 Earnings Call Highlights LeMaitre Vascular NASDAQ: LMAT reported 12% organic sales growth in the third quarter of 2026, driven by higher prices and unit volumes, while reiterating its full-year organic growth outlook and…
zacks.com LeMaitre Vascular (LMAT) Misses Q3 Earnings Estimates LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.65 per share, missing the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.62 per share a year ago.
benzinga.com LeMaitre Vascular Q3 2026 Earnings Call Transcript LeMaitre Vascular (NASDAQ:LMAT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com LeMaitre Vascular Lowers FY2026 GAAP EPS Guidance from $2.84-$2.94 to $2.77-$2.82 vs $2.87 Est; Narrows FY2026 Sales Guidance from $274.300M-$278.300M to $274.800M-$276.800M vs $276.539M Est LeMaitre Vascular (NASDAQ:LMAT) lowers FY2026 GAAP EPS guidance from $2.84-$2.94 to $2.77-$2.82 vs $2.87 analyst estimate. Narrows FY2026 sales outlook from $274.300 million-$278.300 million to…
benzinga.com LeMaitre Vascular Lowers Q4 GAAP EPS Guidance from $0.75-$0.81 to $0.70-$0.75 vs $0.78 Est; Lowers Q4 Sales Guidance from $71.100M-$73.100M to $69.900M-$71.900M vs $72.325M Est LeMaitre Vascular (NASDAQ:LMAT) lowers Q4 GAAP EPS guidance from $0.75-$0.81 to $0.70-$0.75 vs $0.78 analyst estimate. Lowers Q4 sales outlook from $71.100 million-$73.100 million to $69.900…
globenewswire.com LeMaitre Q3 2026 Financial Results BURLINGTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2026 results, announced a…
seekingalpha.com Dividend Income Report: +15.25% And A Listener's Portfolio Roast This month I tried something different on the podcast - a listener sent me one of his portfolios and asked me to roast it. He holds 29 stocks with roughly equal weight, so I built a mock $100,000…
globenewswire.com LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026 BURLINGTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2026 financial results on Wednesday, November 4,…
seekingalpha.com LeMaitre Vascular: The Q2 Miss Hides A Stronger Acquisition Machine LeMaitre Vascular is rated a "Strong Buy" due to its robust M&A-driven business model, high margins, and recent valuation compression. LMAT's strategic shift to larger, higher-multiple acquisitions…
prnewswire.com LeMaitre Vascular Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Customer Data Is Exposed National class action law firm offers free, confidential case evaluations to LeMaitre Vascular investors, tenants, partners, and others whose personal information may have been exposed in the…- benzinga.com L3Harris Technologies Receives 7-Year, $4.7B Lockheed Martin Contract To Produce Propulsion Systems For PAC-3 Missile Segment Enhancement Interceptor L3Harris Technologies (NYSE: LHX) has received an undefinitized contract award from Lockheed Martin, valued at $4.7 billion over seven years, to produce propulsion systems for the PAC-3® Missile…
zacks.com PAHC or LMAT: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and LeMaitre Vascular (LMAT). But which of these two stocks is more…
globenewswire.com LeMaitre to Participate at Upcoming Investor Conferences in September BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.
seekingalpha.com Dividend Champion, Contender, And Challenger Highlights: Week August 16 A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
zacks.com GEHC or LMAT: Which Is the Better Value Stock Right Now? Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the…
seekingalpha.com LeMaitre Vascular: 31% Drawdown On $0.02 Guidance Cut LeMaitre Vascular remains a Buy after a 31% pullback, though I have trimmed my price target to $95-$100 for year-end 2027. The Q2 2026 miss was tied to currency, export blockages, and tissue…
globenewswire.com LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference BURLINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will hold investor meetings at the 11th Annual Needham Virtual MedTech &…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Zhengye Biotechnology (NASDAQ:ZYBT) stock increased by 107.0% to $2.65 during Wednesday's regular session. The company's market cap stands at $60.6 million. Bluejay Diagnostics (NASDAQ:BJDX)…
benzinga.com Wells Fargo Maintains Equal-Weight on LeMaitre Vascular, Lowers Price Target to $94 Wells Fargo analyst Nathan Treybeck maintains LeMaitre Vascular (NASDAQ:LMAT) with a Equal-Weight and lowers the price target from $104 to $94.
seekingalpha.com LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript
marketbeat.com LeMaitre Vascular Q2 Earnings Call Highlights LeMaitre Vascular NASDAQ: LMAT reported second-quarter 2026 results marked by 10% organic revenue growth, record operating income and continued expansion of its Artegraft product line, while foreign…
zacks.com LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Lag Estimates LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.74 per share, missing the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.6 per share a year ago.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday's after-market session. American Well (NYSE:AMWL) stock rose 12.76% to $11.75. The market value of their…
benzinga.com LeMaitre Vascular Sees Q4 GAAP EPS $0.75-$0.81 vs $0.78 Est; Sees Sales $71.100M-$73.100M vs $72.745M Est LeMaitre Vascular (NASDAQ:LMAT) is looking for Q4 GAAP EPS of $0.75-$0.81 vs $0.78 analyst estimate. sees sales of $71.100 million-$73.100 million vs $72.745 million analyst estimate.- benzinga.com LeMaitre Vascular Sees Q3 GAAP EPS $0.66-$0.71 vs $0.73 Est; Sees Sales $66.300M-$68.300M vs $69.246M Est LeMaitre Vascular (NASDAQ:LMAT) is looking for Q3 GAAP EPS of $0.66-$0.71 vs $0.73 analyst estimate. sees sales of $66.300 million-$68.300 million vs $69.246 million analyst estimate.
benzinga.com LeMaitre Vascular Lowers FY2026 GAAP EPS Guidance from $2.93-$3.08 to $2.84-$2.94 vs $2.97 Est; Lowers FY2026 Sales Guidance from $277.000M-$283.000M to $274.300M-$278.300M vs $279.948M Est LeMaitre Vascular (NASDAQ:LMAT) lowers FY2026 GAAP EPS guidance from $2.93-$3.08 to $2.84-$2.94 vs $2.97 analyst estimate. Lowers FY2026 sales outlook from $277.000 million-$283.000 million to…- benzinga.com LeMaitre Vascular Q2 EPS $0.74 Misses $0.79 Estimate, Sales $70.382M Miss $70.973M Estimate LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.74 per share which missed the analyst consensus estimate of $0.79 by 6.33 percent. This is a 23.33 percent increase over earnings of…
globenewswire.com LeMaitre Q2 2026 Financial Results BURLINGTON, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2026 results, announced a…
globenewswire.com LeMaitre Will Announce Second Quarter 2026 Earnings Results on August 4, 2026 BURLINGTON, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2026 financial results on Tuesday, August 4, 2026,…- benzinga.com Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $120 Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outperform and raises the price target from $105 to $120.
benzinga.com Citizens Maintains Market Outperform on LeMaitre Vascular, Raises Price Target to $127 Citizens analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:LMAT) with a Market Outperform and raises the price target from $118 to $127.- benzinga.com Wells Fargo Maintains Equal-Weight on LeMaitre Vascular, Raises Price Target to $104 Wells Fargo analyst Nathan Treybeck maintains LeMaitre Vascular (NASDAQ:LMAT) with a Equal-Weight and raises the price target from $94 to $104.
- benzinga.com LeMaitre Vascular Reports Q1 2026 Results: Full Earnings Call Transcript
benzinga.com LeMaitre Vascular Sees Q2 GAAP EPS $0.79-$0.84 vs $0.75 Est; Sees Sales $70.500M-$72.500M vs $71.105M Est LeMaitre Vascular (NASDAQ:LMAT) is looking for Q2 GAAP EPS of $0.79-$0.84 vs $0.75 analyst estimate. sees sales of $70.500 million-$72.500 million vs $71.105 million analyst estimate.- benzinga.com LeMaitre Vascular Raises FY2026 GAAP EPS Guidance from $2.81-$3.01 to $2.93-$3.08 vs $2.90 Est; Narrows FY2026 Sales Guidance from $276.000M-$284.000M to $277.000M-$283.000M vs $279.492M Est LeMaitre Vascular (NASDAQ:LMAT) raises FY2026 GAAP EPS guidance from $2.81-$3.01 to $2.93-$3.08 vs $2.90 analyst estimate. Narrows FY2026 sales outlook from $276.000 million-$284.000 million to…
- benzinga.com LeMaitre Vascular Q1 EPS $0.68 Beats $0.66 Estimate, Sales $66.551M Beat $66.530M Estimate LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.66 by 3.03 percent. This is a 41.67 percent increase over earnings of…
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $105 Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outperform and raises the price target from $95 to $105.
benzinga.com J M Smucker, Krispy Kreme, Shake Shack, Accenture And Other Big Stocks Moving Higher On Thursday 
benzinga.com Breaking Down LeMaitre Vascular: 4 Analysts Share Their Views - benzinga.com Roth Capital Reiterates Buy on LeMaitre Vascular, Raises Price Target to $117 Roth Capital analyst Kyle Bauser reiterates LeMaitre Vascular (NASDAQ:LMAT) with a Buy and raises the price target from $108 to $117.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Wells Fargo Maintains Equal-Weight on LeMaitre Vascular, Raises Price Target to $94 Wells Fargo analyst Nathan Treybeck maintains LeMaitre Vascular (NASDAQ:LMAT) with a Equal-Weight and raises the price target from $87 to $94.
benzinga.com Citizens Maintains Market Outperform on LeMaitre Vascular, Raises Price Target to $118 Citizens analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:LMAT) with a Market Outperform and raises the price target from $113 to $118.- benzinga.com LeMaitre Vascular Sees FY2026 GAAP EPS $2.81-$3.01 vs $2.58 Est; Sees Sales $276.000M-$284.000M vs $270.499M Est LeMaitre Vascular (NASDAQ:LMAT) is looking for FY2026 GAAP EPS of $2.81-$3.01 vs $2.58 analyst estimate. sees sales of $276.000 million-$284.000 million vs $270.499 million analyst estimate.
- benzinga.com LeMaitre Vascular Sees Q1 GAAP EPS $0.64-$0.69 vs $0.61 Est; Sees Sales $65.600M-$67.600M vs $65.855M Est LeMaitre Vascular (NASDAQ:LMAT) is looking for Q1 GAAP EPS of $0.64-$0.69 vs $0.61 analyst estimate. sees sales of $65.600 million-$67.600 million vs $65.855 million analyst estimate.